Routine COVID-19 testing may not be necessary for most cancer patients.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
02 12 2021
02 12 2021
Historique:
received:
16
07
2021
accepted:
17
11
2021
entrez:
3
12
2021
pubmed:
4
12
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Cancer patients are at risk for severe complications or death from COVID-19 infection. Therefore, the need for routine COVID-19 testing in this population was evaluated. Between 1st August and 30th October 2020, 150 cancer patients were included. Symptoms of COVID-19 infection were evaluated. All eligible individuals went through RT-PCR and serological tests for COVID-19. At the same time, 920 non-cancer patients were recruited from a random sample of individuals who were subject to routine molecular and anti-body screening tests. Of 150 cancer patients, 7 (4.7%) were RT-PCR positive. Comorbidity made a significant difference in the RT-PCR positivity of cancer patients, 71.4% positive versus 25.8% negative (P-value = 0.02). The average age for negative and positive groups was 53.3 and 58.2 respectively (P-value = 0.01). No significant difference was observed between cancer and non-cancer patients regarding COVID-19 antibody tests. However, cancer patients were 3 times less likely to have a positive RT-PCR test result OR = 0.33 (CI: 0.15-0.73). The probability of cancer patients having a positive routine test was significantly lower than non-cancer patients, and the concept that all cancer patients should be routinely tested for COVID-19 may be incorrect. Nevertheless, there may be a subgroup of patients with comorbidities or older age who may benefit from routine COVID-19 testing. Importantly, these results could not be subjected to multivariate analysis.
Identifiants
pubmed: 34857785
doi: 10.1038/s41598-021-02692-3
pii: 10.1038/s41598-021-02692-3
pmc: PMC8640074
doi:
Substances chimiques
Immunoglobulin G
0
Immunoglobulin M
0
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
23294Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Informations de copyright
© 2021. The Author(s).
Références
Ann Oncol. 2020 Jul;31(7):894-901
pubmed: 32224151
Eur J Cancer. 2020 Nov;139:43-50
pubmed: 32971510
SN Compr Clin Med. 2020 Jun 25;:1-8
pubmed: 32838147
JAMA Oncol. 2020 Jul 1;6(7):1108-1110
pubmed: 32211820
Crit Rev Oncol Hematol. 2020 Sep;153:103059
pubmed: 32711241
Allergy. 2021 Feb;76(2):428-455
pubmed: 33185910
Cancer Cell. 2020 Aug 10;38(2):161-163
pubmed: 32710820
Tob Induc Dis. 2020 Mar 20;18:20
pubmed: 32206052
Ecancermedicalscience. 2020 Sep 09;14:1100
pubmed: 33082850
Cancer Med. 2020 Nov;9(21):8020-8028
pubmed: 33022856
Crit Rev Oncol Hematol. 2020 Jun;150:102972
pubmed: 32344317
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Infect Chemother. 2020 Jun;52(2):154-164
pubmed: 32537961
JNCI Cancer Spectr. 2021 Jan 06;5(1):pkaa090
pubmed: 33604509
Cancer Biol Med. 2020 Aug 15;17(3):519-527
pubmed: 32944387
Cancer Rep (Hoboken). 2021 Oct;4(5):e1378
pubmed: 33742793
Sci Data. 2020 Oct 8;7(1):345
pubmed: 33033256
Hematol Oncol Stem Cell Ther. 2020 Jul 30;:
pubmed: 32745466